Isarna Therapeutics enters into a strategic manufacturing agreement with Sanofi

13-Jan-2014 - Germany

Isarna Therapeutics GmbH announced that it has signed a strategic manufacturing agreement with Sanofi under which Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna, enabling Isarna to advance its promising next generation ASOs rapidly into clinical trials. Financial details of the agreement have not been disclosed.

“At Isarna, we are convinced that the best possible manufacturing is critical as we seek to maintain an accelerated timeline for product development,” explained Dr. Philippe Calais, CEO of Isarna Therapeutics. “Having Sanofi as our partner for the production of these exciting new immunotherapy compounds is a firm step forward in the development of the company and is consistent with our strategy to establish key relationships with leaders in the industry.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...